Content about Mycophenolate mofetil

August 22, 2013

Astellas Pharma has introduced a new drug for preventing the body from rejecting transplanted organs, the company said.

NORTHBROOK, Ill. — Astellas Pharma has introduced a new drug for preventing the body from rejecting transplanted organs, the company said Thursday.

The drug maker announced the availability of Astagraf XL (tacrolimus) extended-release capsules in pharmacies. The drug is designed for use in kidney transplant patients with Genenetech's CellCept (mycophenolate mofetil) and corticosteroids, with or without induction of Novartis' Simulect (basiliximab).

July 22, 2013

The Food and Drug Administration has approved a drug made by Japanese drug maker Astellas for preventing the body from rejecting transplanted organs, the company said.

NORTHBROOK, Ill. — The Food and Drug Administration has approved a drug made by Japanese drug maker Astellas for preventing the body from rejecting transplanted organs, the company said.

Astellas announced through a U.S. subsidiary that the FDA had approved Astagraf XLTM (tacrolimus) extended-release capsules for preventing rejection of transplanted kidneys, for use with Genentech's CellCept (mycophenolate mofetil) and corticosteroids, with or without Simulect (basiliximab), a biotech drug made by Swiss drug maker Novartis.

June 16, 2011

The Food and Drug Administration has approved a new drug for preventing organ rejection in kidney transplant patients, the agency said Wednesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for preventing organ rejection in kidney transplant patients, the agency said Wednesday.

The FDA approved Bristol-Myers Squibb’s Nulojix (belatacept), for preventing acute rejection in adult patients. The drug is approved for use with other immune system-suppressing drugs, specifically Novartis’ Simulect (basiliximab), Genentech’s CellCept (mycophenolate mofetil) and corticosteroids.